CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Radius Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Radius Health Inc
Attn: Principal Finance Officer
22 Boston Wharf Road, 7Th Floor
Phone: (617) 551-4000p:617 551-4000 BOSTON, MA  02210  United States Fax: (617) 551-4701f:617 551-4701
This company ceased filing statements with the SEC on 8/25/2022.
On 8/15/2022 the Company was acquired by Gurnet Point Capital and Patient Square Capital
This company is no longer actively traded on any major stock exchange.
Business Summary
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
6770 Blank checks
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Owen P.Hughes 47 3/23/2020 4/1/2013
President, Chief Executive Officer, Director G. KellyMartin 63 4/28/2020 4/28/2020
Chief Financial Officer, Vice President, Treasurer Mark W.Conley 60 3/1/2022 3/1/2022
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Radius Health (Ireland) Limited
Radius Pharmaceuticals Bermuda Ltd.
RDUS

General Information
Number of Employees: 293 (As of 12/31/2021)
Outstanding Shares: 47,620,498 (As of 8/4/2022)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 800145732
Fax Number: (617) 551-4701


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024